Compare NTLA & TMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | TMC |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2016 | 2020 |
| Metric | NTLA | TMC |
|---|---|---|
| Price | $13.11 | $5.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 5 |
| Target Price | ★ $20.02 | $8.85 |
| AVG Volume (30 Days) | 3.4M | ★ 6.4M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.43 | ★ 232.00 |
| EPS | N/A | ★ 0.19 |
| Revenue | ★ $67,671,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $62.75 | N/A |
| P/E Ratio | ★ N/A | $26.07 |
| Revenue Growth | ★ 16.92 | N/A |
| 52 Week Low | $7.95 | $3.40 |
| 52 Week High | $28.24 | $11.35 |
| Indicator | NTLA | TMC |
|---|---|---|
| Relative Strength Index (RSI) | 56.01 | 66.58 |
| Support Level | $11.55 | $4.81 |
| Resistance Level | $15.52 | $6.51 |
| Average True Range (ATR) | 0.61 | 0.32 |
| MACD | 0.24 | 0.12 |
| Stochastic Oscillator | 72.84 | 96.67 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.